Sales of testosterone boosters, or “Low T” drugs, could reach $5 billion by 2017, according to the New York Times. Testosterone boosters, which include drugs such as AndroGel and Androderm, reached $2 billion in sales in 2012 —Low T prescriptions have tripled since 2001.
Many doctors have expressed concern at the growing rate of testosterone booster prescriptions, particularly to patients who have not been clinically tested for low testosterone, also known as hypogonadism. As many as 25% of low testosterone drugs are prescribed without a patient receiving a blood test necessary for the diagnosis.
Recent studies have found that patients could be at an increased risk of serious side effects associated with testosterone boosters. Manufacturers are now facing multiple testosterone booster lawsuits alleging that the companies failed to warn doctors and patients of the increased risks of heart attacks and stroke associated with Low T drugs.